FIGURE 7 from B7-H3–Targeting Chimeric Antigen Receptors Epstein-Barr Virus–specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3–positive Solid Tumors

In vivo targeting of allogeneic myeloid cells by B7H3.CAR EBVSTs is linked to a lower risk of CRS. A, IVIS monitoring was performed to track tumor progression. Bioluminescence images of tumor burden in mice injected intravenously with NALM-6 (left) or HT-29 (right) at days −1, 2, and 5 posttreatment. B, Average tumor burden represented in mice of each treatment group injected with NALM-6 (top) or HT-29 (bottom). Body weight measurements of NALM-6 (C) or HT-29-injected (D) mice posttreatment. E, Serum levels of human cytokines and chemokines at 3 days posttreatment as quantified by multiplex bead immunoassay. F, Total counts of dendritic cells (top), monocytes (middle), and neutrophils (bottom) in blood, bone marrow, spleen, and liver of each treatment groups quantified by flow cytometry. G, B7-H3 expression on dendritic cells (top), monocytes (middle), and neutrophils (bottom) in blood, bone marrow, spleen, and liver after treatment, quantified by flow cytometry. Data comprise of up to 6–9 mice in each treatment arm. For B–D, groups were compared using two-way ANOVA with Tukey test for multiple comparisons test. Comparison and P values between untreated versus UT T, untreated versus B7H3.CAR EBVSTs and UT T versus B7H3.CAR EBVSTs groups is represented in black, blue, and red, respectively. For E–G, groups were compared using one-way ANOVA with Tukey test for multiple comparisons test. *, P P P P